Released Nov 14, 2022, after the close
10-Q filed Nov 14, 2022, 45 days after period end · 0001140361-22-041399
Q3 2022 · 10-Q
Revenue$0.00$0.00 no prior Q3 2021 on fileno prior Q2 2022 on file
Net Income-$7.32M-$7.32M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$2.49-$2.49 N/M vs Q3 2021N/M vs Q2 2022
Gross Profit$0—
Operating Income-$8,304,000N/M
Operating Cash Flowderived-$6,116,000N/M
Free Cash Flowderived-$6,159,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $0.00 | — | $1.48M | $4.58M |
| Net Income | -$7.32M | -$85.99M | -$2.02M | -$351.00K |
| EPS Diluted | -$2.49 | -$34.03 | -$0.11 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR